Results 81 to 90 of about 11,492 (188)

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang   +37 more
wiley   +1 more source

A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma

Frontiers in Immunology
IntroductionPatients with severe asthma may benefit from targeted biological therapies. However, personalized therapy in children and adolescents with asthma, based on individual susceptibility to molecular mechanisms addressed by different biologicals ...
Boris Gole, Larisa Goričan, Gregor Jezernik, Mario Gorenjak, Anja Bizjak, Vojko Berce, Vojko Berce, Maja Skerbinjek Kavalar, Michael Kabesch, Erik Melén, Korneliusz Golebski, Cornelius M. van Drunen, Anke Hilse Maitland-van der Zee, Anke Hilse Maitland-van der Zee, Susanne Reinartz, Susanne J. H. Vijverberg, Susanne J. H. Vijverberg, Uroš Potočnik, Uroš Potočnik, Uroš Potočnik   +19 more
doaj   +1 more source

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study

Allergology International, 2018
Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double ...
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil   +10 more
doaj   +1 more source

Changes in antigen-specific T cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab [PDF]

, 2013
Food allergy is a major public health problem for which there is no effective treatment. We examined the immunological changes that occurred in a group of children with significant cow’s milk allergy undergoing a novel and rapid high dose oral ...
Bedoret, Denis, DeKruyff, Rosemarie H., Hamilton, R, Hoyte, E G, Nadeau, K C, Schneider, Lynda C., Shaw, V, Singh, A K, Umetsu, Dale T.   +8 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study [PDF]

, 2016
BACKGROUND: Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and
Chien-Da Huang, Erin Chang, Han-Pin Kuo, Hao-Cheng Chen   +3 more
core   +1 more source

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

Allergy, EarlyView.
Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian   +8 more
wiley   +1 more source

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

Clinical &Experimental Allergy, EarlyView.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan, Shengyang Yao, Lisha Li, Yongshi Yang, Wenchao Guan, Yin Wang, Xiaoshang Lou, Chuanhe Liu, Yanmin Bao, Shijie Zhuang, Li Sha, Ruonan Chai, Rongfei Zhu, Kai Guan   +13 more
wiley   +1 more source

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Risk Management and Healthcare Policy, 2020
Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM   +7 more
doaj  

Outcomes of off-label drug uses in hospitals: a multicentric prospective study [PDF]

, 2015
Purpose: The study aims to assess the clinical evidence, outcome and cost of off-label use of medicines in the hospital setting. Methods: A multicentric prospective cohort study of patients treated with off-label medicines was carried out in five ...
Agustí, Antonia, Alerany, C., Bonafont, X., Bosch Gil, Josep Àngel, Cano Marron, S. M., Danés, Immaculada, Ferrer, Assumpta, Gratacós, L., Martínez, J., Olmo, M., Pérez, A., Valderrama, A., Vallano Ferraz, Antonio   +12 more
core   +1 more source